ASTRAZENECA VACCINE FALLS FROM GRACE

The Highwire with Del Bigtree

News, Society & Culture, Health & Fitness

4.9 • 3.4K Ratings

🗓️ 27 March 2021

⏱️ 13 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

It’s been a tough month for the AstraZeneca #Covid19 vaccine. Jefferey Jaxen breaks down the serious side effect that paused the vaccine rollout in 24 countries, and why NIAID called the company out for using outdated and misleading trial data when disclosing the efficacy of the vaccine.

Transcript

Click on a timestamp to play from that location

0:00.0	This is a story for us, been going on, it's been unfolding for a couple weeks.
0:04.9	So let's catch up with that and check out what it looked like in the news.
0:07.4	This is from AstraZeneca, some of the information that came out from them lately.
0:11.2	Several countries are imposing their rollouts of the AstraZeneca vaccine.
0:15.0	France, Germany and Italy have become the latest countries to suspend use of the Oxford
0:20.6	AstraZeneca JAP.
0:22.1	Denmark, Norway and Iceland have already suspended the vaccine.
0:25.4	The Republic of Ireland and the Netherlands brings the total number of European nations
0:29.2	in total to have paused their rollouts of the vaccination to 9.
0:33.2	The main concern is that there are all kinds of possible side effects that are being reported.
0:38.5	There have been new cases in recent days of people who have developed what they describe
0:43.2	as a special type of a rare blood clot in the brain following vaccination with the AstraZeneca.
0:50.2	The company released good news from its US clinical trial results Monday, 79% effectiveness
0:56.7	against COVID-19, but overnight the NIH saying it's concerned about the initial data.
1:03.2	Health officials say they are worried results from the company's US trial included outdated
1:08.9	information.
1:09.9	They were concerned that the efficacy numbers may have been based on outdated data.
1:14.5	They then notified our top government agencies and asked the company to explain these numbers.
1:21.1	This company has run into problems in the past with the data.
1:23.4	I don't think you guys remember back in November.
1:25.2	I had that huge issue where some of the efficacy came because they were incorrectly dosing
1:30.2	some patients.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Highwire with Del Bigtree, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Highwire with Del Bigtree and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.